WO1997040462A2 - Correlating polymorphic forms with multiple phenotypes - Google Patents
Correlating polymorphic forms with multiple phenotypes Download PDFInfo
- Publication number
- WO1997040462A2 WO1997040462A2 PCT/US1997/006457 US9706457W WO9740462A2 WO 1997040462 A2 WO1997040462 A2 WO 1997040462A2 US 9706457 W US9706457 W US 9706457W WO 9740462 A2 WO9740462 A2 WO 9740462A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenotypes
- subject
- disease
- phenotype
- population
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Definitions
- genes correlating with multiple phenotypes include ApoE (heart disease and Alzheimer's disease), the AT gene (ataxis, telangiectasias, radiation sensitivity, leukemia, breast cancer and diabetes); the brcal gene (breast and ovarian cancer); Huntington's gene (movement disorder, dementia and psychosis); and the leptin receptor (diabetes, obesity).
- ApoE heart disease and Alzheimer's disease
- the AT gene ataxis, telangiectasias, radiation sensitivity, leukemia, breast cancer and diabetes
- the brcal gene breast cancer
- Huntington's gene moving disorder, dementia and psychosis
- leptin receptor diabetes, obesity
- diseases correlated with multiple genes include heart disease, Alzheimer's disease, hypertension, diabetes, and obesity.
- polymorphic form refers to one of the forms of a polymorphism existing at a genetic locus in a population of organisms. At the molecular level, when two homologous segments of genetic material have different nucleotide sequences, the segments exhibit polymorphism and each different sequence is a polymorphic form.
- An example of polymorphic forms is the different sequences for a gene that encode polypeptides of different amino acids sequences, or functional RNA molecules having different sequences. The differences may reflect nucleotide substitutions, insertions or deletions between the different sequences.
- a “label” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
- useful labels include 32 P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available (e.g., by inco ⁇ orating a radio-label into the peptide, and used to detect antibodies specifically reactive with the peptide).
- a label often generates a measurable signal, such as radioactivity, fluorescent light or enzyme activity, which can be used to quantitate the amount of bound label.
- the polymo ⁇ hic form occurs within a gene or putative gene of unknown function, for example, a newly sequenced open reading frame.
- Lhe polymo ⁇ hic form may represent a variation preventing expression of a functional gene product.
- Other times the genotypic marker occurs within a gene that has been correlated with certain phenotypes, but for which it is believed that correlations with additional phenotypes can be found.
- the polymo ⁇ hic form has no known statistically significant correlation with a disease phenotype.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Zoology (AREA)
- Ecology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Wood Science & Technology (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9538193A JP2000508912A (en) | 1996-04-19 | 1997-04-18 | Correlating polymorphic forms with multiple phenotypes |
EP97921244A EP0897567A2 (en) | 1996-04-19 | 1997-04-18 | Correlating polymorphic forms with multiple phenotypes |
AU27341/97A AU2734197A (en) | 1996-04-19 | 1997-04-18 | Correlating polymorphic forms with multiple phenotypes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63651796A | 1996-04-19 | 1996-04-19 | |
US08/636,517 | 1996-04-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997040462A2 true WO1997040462A2 (en) | 1997-10-30 |
WO1997040462A3 WO1997040462A3 (en) | 1998-03-05 |
Family
ID=24552242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/006457 WO1997040462A2 (en) | 1996-04-19 | 1997-04-18 | Correlating polymorphic forms with multiple phenotypes |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0897567A2 (en) |
JP (1) | JP2000508912A (en) |
AU (1) | AU2734197A (en) |
WO (1) | WO1997040462A2 (en) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006769A2 (en) * | 1998-07-25 | 2000-02-10 | Astrazeneca | Human ccr-2 gene polymorphisms |
WO2000017392A1 (en) * | 1998-09-19 | 2000-03-30 | Astrazeneca Ab | Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases |
WO2000017393A1 (en) * | 1998-09-19 | 2000-03-30 | Astrazeneca Ab | Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
WO2000017394A1 (en) * | 1998-09-19 | 2000-03-30 | Astrazeneca Ab | Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
WO2001027857A2 (en) | 1999-10-13 | 2001-04-19 | Sequenom, Inc. | Methods for generating databases and databases for identifying polymorphic genetic markers |
EP1118680A1 (en) * | 2000-01-18 | 2001-07-25 | AstraZeneca AB | Method for the diagnosis of polymorphisms in the human PDH E1alpha gene |
EP1118678A1 (en) * | 2000-01-18 | 2001-07-25 | AstraZeneca AB | Method for diagnosing polymorphisms in the human PDH E1 beta gene |
EP1118679A1 (en) * | 2000-01-18 | 2001-07-25 | AstraZeneca AB | Method for diagnosing polymorphisms in the human PDH E2 gene |
EP1122318A2 (en) * | 2000-02-03 | 2001-08-08 | AstraZeneca AB | Diagnostic method for the detection of polymorphisms related to the human urokinase plasminogen activator receptor |
EP1130122A2 (en) * | 2000-02-17 | 2001-09-05 | AstraZeneca AB | Methods for the diagnosis of polymorphisms in the human EP1-R gene |
WO2002006523A2 (en) | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | Method for detecting pre-disposition to hepatotoxicity |
WO2002020835A2 (en) * | 2000-09-04 | 2002-03-14 | Glaxo Group Limited | Genetic study |
EP1233364A2 (en) * | 1999-06-25 | 2002-08-21 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
WO2003070978A1 (en) * | 2002-02-25 | 2003-08-28 | Norbert Dahmen | Method for identifying side-effect relevant genetic marker profiles |
WO2003079241A1 (en) * | 2002-03-18 | 2003-09-25 | Diatech Pty Ltd | Assessing data sets |
WO2004015130A2 (en) * | 2002-08-07 | 2004-02-19 | Exelixis | Modulators of rabggt and methods of use thereof |
EP1199372A3 (en) * | 2000-10-21 | 2004-05-12 | AstraZeneca AB | Polymorphisms in the human P2X7 gene |
WO2005017199A1 (en) * | 2003-08-14 | 2005-02-24 | Mars, Incorporated | Iga allelic variants |
US6931326B1 (en) | 2000-06-26 | 2005-08-16 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
WO2005111241A2 (en) | 2004-05-07 | 2005-11-24 | Applera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
US7058517B1 (en) | 1999-06-25 | 2006-06-06 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
EP1741722A2 (en) * | 2000-10-21 | 2007-01-10 | AstraZeneca AB | Polymorphisms in the human P2X7 gene |
WO2007050705A2 (en) | 2005-10-26 | 2007-05-03 | Celera Diagnostics, Llc. | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
WO2008051511A2 (en) | 2006-10-20 | 2008-05-02 | Applera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
WO2009061799A2 (en) | 2007-11-05 | 2009-05-14 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
EP2113572A1 (en) | 2005-03-11 | 2009-11-04 | Celera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
EP2151507A1 (en) | 2002-12-20 | 2010-02-10 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2186913A2 (en) | 2003-11-26 | 2010-05-19 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
EP2194144A1 (en) | 2004-11-16 | 2010-06-09 | Trustees Of Boston University | Roles for dual Endothelin-1/Angiotensin II receptor (DEAR) in hypertension and angiogenesis |
WO2011022633A2 (en) | 2009-08-21 | 2011-02-24 | Smithkline Beecham (Cork) Ltd. | Method of threating cancer |
WO2011133418A1 (en) | 2010-04-19 | 2011-10-27 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
WO2011147763A1 (en) | 2010-05-25 | 2011-12-01 | Glaxo Group Limited | Biomarkers |
WO2012061502A2 (en) | 2010-11-02 | 2012-05-10 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
EP2471953A1 (en) | 2005-09-23 | 2012-07-04 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
WO2013113796A1 (en) | 2012-01-31 | 2013-08-08 | Smithkline Beecham (Cork) Limited | Method of treating cancer |
EP2733222A1 (en) | 2008-07-09 | 2014-05-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
EP3048175A1 (en) | 2008-02-20 | 2016-07-27 | Celera Corporation | Genetic polymorphism associated with stroke, therapy based on the detection of the polymorphism and use of kits containing reagents for detecting the polymorphism |
US10706956B2 (en) | 2010-05-25 | 2020-07-07 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
US10726945B2 (en) | 2010-05-25 | 2020-07-28 | The Regents Of The University Of California | BAMBAM: parallel comparative analysis of high-throughput sequencing data |
EP3795695A1 (en) | 2014-07-30 | 2021-03-24 | F. Hoffmann-La Roche AG | Genetic markers for predicting responsiveness to therapy |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2387277C (en) * | 2001-05-25 | 2015-03-03 | Hitachi, Ltd. | Information processing system using nucleotide sequence-related information |
JP2003067389A (en) * | 2001-06-29 | 2003-03-07 | Dainakomu:Kk | Method for genopolytypic-related analysis, and program therefor |
FI20012593A0 (en) * | 2001-12-28 | 2001-12-28 | Pertti Laehteenmaeki | A method and system for providing a nutrition information service |
FI20021031A (en) * | 2001-12-28 | 2003-06-29 | Pertti Laehteenmaeki | Nutritional Machine |
US20040146870A1 (en) * | 2003-01-27 | 2004-07-29 | Guochun Liao | Systems and methods for predicting specific genetic loci that affect phenotypic traits |
US9394565B2 (en) | 2003-09-05 | 2016-07-19 | Agena Bioscience, Inc. | Allele-specific sequence variation analysis |
AU2005230936B2 (en) | 2004-03-26 | 2010-08-05 | Agena Bioscience, Inc. | Base specific cleavage of methylation-specific amplification products in combination with mass analysis |
-
1997
- 1997-04-18 JP JP9538193A patent/JP2000508912A/en active Pending
- 1997-04-18 WO PCT/US1997/006457 patent/WO1997040462A2/en not_active Application Discontinuation
- 1997-04-18 EP EP97921244A patent/EP0897567A2/en not_active Ceased
- 1997-04-18 AU AU27341/97A patent/AU2734197A/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
COMPUTERS AND BIOMEDICAL RESEARCH, vol. 27, April 1994, US, pages 97-115, XP002039573 RITTER ET AL: "prototype implementation of the integrated genomic database" * |
COMPUTERS AND BIOMEDICAL RESEARCH, vol. 29, no. 4, August 1996, US, pages 327-337, XP002039576 CHEUNG ET AL: "phenodb : an integrated client/server database for linkage and population genetics" * |
INTERNATIONAL JOURNAL OF MAN-MACHINE STUDIES, vol. 23, no. 4, 1985, UK, pages 551-561, XP002039574 MUNAKATA: "knowledge-based systems for genetics" * |
PROCEEDINGS OF THE 27TH SYMPOSIUM ON THE INTERFACE COMPUTING SCIENCE AND STATISTICS, 21 June 1995, US, pages 259-263, XP002039575 GALFALVY ET AL: "a statistical environment for multivariate analyses" * |
Cited By (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006769A2 (en) * | 1998-07-25 | 2000-02-10 | Astrazeneca | Human ccr-2 gene polymorphisms |
WO2000006769A3 (en) * | 1998-07-25 | 2000-05-11 | Zeneca Ltd | Human ccr-2 gene polymorphisms |
WO2000017392A1 (en) * | 1998-09-19 | 2000-03-30 | Astrazeneca Ab | Polymorphisms in the human vcam-1 gene, suitable for diagnosis and treatment of vcam-1 ligand mediated diseases |
WO2000017393A1 (en) * | 1998-09-19 | 2000-03-30 | Astrazeneca Ab | Polymorphisms in the human beta1 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
WO2000017394A1 (en) * | 1998-09-19 | 2000-03-30 | Astrazeneca Ab | Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases |
EP1233364A3 (en) * | 1999-06-25 | 2004-11-10 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
US7058517B1 (en) | 1999-06-25 | 2006-06-06 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
EP1233365A3 (en) * | 1999-06-25 | 2004-11-17 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
EP1233365A2 (en) * | 1999-06-25 | 2002-08-21 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
EP1233364A2 (en) * | 1999-06-25 | 2002-08-21 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
WO2001027857A2 (en) | 1999-10-13 | 2001-04-19 | Sequenom, Inc. | Methods for generating databases and databases for identifying polymorphic genetic markers |
JP2003519829A (en) * | 1999-10-13 | 2003-06-24 | シークエノム・インコーポレーテツド | Methods for creating a database and a database for identifying polymorphic genetic markers |
WO2001027857A3 (en) * | 1999-10-13 | 2002-10-03 | Sequenom Inc | Methods for generating databases and databases for identifying polymorphic genetic markers |
EP1118680A1 (en) * | 2000-01-18 | 2001-07-25 | AstraZeneca AB | Method for the diagnosis of polymorphisms in the human PDH E1alpha gene |
EP1118678A1 (en) * | 2000-01-18 | 2001-07-25 | AstraZeneca AB | Method for diagnosing polymorphisms in the human PDH E1 beta gene |
EP1118679A1 (en) * | 2000-01-18 | 2001-07-25 | AstraZeneca AB | Method for diagnosing polymorphisms in the human PDH E2 gene |
EP1122318A2 (en) * | 2000-02-03 | 2001-08-08 | AstraZeneca AB | Diagnostic method for the detection of polymorphisms related to the human urokinase plasminogen activator receptor |
EP1122318A3 (en) * | 2000-02-03 | 2001-09-26 | AstraZeneca AB | Diagnostic method for the detection of polymorphisms related to the human urokinase plasminogen activator receptor |
EP1130122A2 (en) * | 2000-02-17 | 2001-09-05 | AstraZeneca AB | Methods for the diagnosis of polymorphisms in the human EP1-R gene |
EP1130122A3 (en) * | 2000-02-17 | 2001-10-17 | AstraZeneca AB | Methods for the diagnosis of polymorphisms in the human EP1-R gene |
US6931326B1 (en) | 2000-06-26 | 2005-08-16 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
WO2002006523A2 (en) | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | Method for detecting pre-disposition to hepatotoxicity |
WO2002020835A3 (en) * | 2000-09-04 | 2003-10-09 | Glaxo Group Ltd | Genetic study |
WO2002020835A2 (en) * | 2000-09-04 | 2002-03-14 | Glaxo Group Limited | Genetic study |
EP1199372A3 (en) * | 2000-10-21 | 2004-05-12 | AstraZeneca AB | Polymorphisms in the human P2X7 gene |
EP1741722A3 (en) * | 2000-10-21 | 2007-03-14 | AstraZeneca AB | Polymorphisms in the human P2X7 gene |
EP1741722A2 (en) * | 2000-10-21 | 2007-01-10 | AstraZeneca AB | Polymorphisms in the human P2X7 gene |
WO2003070978A1 (en) * | 2002-02-25 | 2003-08-28 | Norbert Dahmen | Method for identifying side-effect relevant genetic marker profiles |
WO2003079241A1 (en) * | 2002-03-18 | 2003-09-25 | Diatech Pty Ltd | Assessing data sets |
WO2004015130A2 (en) * | 2002-08-07 | 2004-02-19 | Exelixis | Modulators of rabggt and methods of use thereof |
WO2004015130A3 (en) * | 2002-08-07 | 2004-10-14 | Exelixis | Modulators of rabggt and methods of use thereof |
EP2500440A2 (en) | 2002-12-20 | 2012-09-19 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2474632A2 (en) | 2002-12-20 | 2012-07-11 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2474631A2 (en) | 2002-12-20 | 2012-07-11 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2474630A2 (en) | 2002-12-20 | 2012-07-11 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP2151507A1 (en) | 2002-12-20 | 2010-02-10 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
WO2005017199A1 (en) * | 2003-08-14 | 2005-02-24 | Mars, Incorporated | Iga allelic variants |
EP2386657A2 (en) | 2003-11-26 | 2011-11-16 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP2386656A2 (en) | 2003-11-26 | 2011-11-16 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP2405023A2 (en) | 2003-11-26 | 2012-01-11 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP2386658A2 (en) | 2003-11-26 | 2011-11-16 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
EP2186913A2 (en) | 2003-11-26 | 2010-05-19 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
EP2386659A2 (en) | 2003-11-26 | 2011-11-16 | Celera Corporation | Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof |
WO2005111241A2 (en) | 2004-05-07 | 2005-11-24 | Applera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
EP2412826A2 (en) | 2004-05-07 | 2012-02-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
EP2412827A2 (en) | 2004-05-07 | 2012-02-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
EP2423326A2 (en) | 2004-05-07 | 2012-02-29 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
EP2423327A2 (en) | 2004-05-07 | 2012-02-29 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
US8956609B2 (en) | 2004-11-16 | 2015-02-17 | Trustees Of Boston University | Roles for Dual Endothelin-1/Angiotensin II Receptor (Dear) in hypertension and angiogenesis |
EP2194144A1 (en) | 2004-11-16 | 2010-06-09 | Trustees Of Boston University | Roles for dual Endothelin-1/Angiotensin II receptor (DEAR) in hypertension and angiogenesis |
EP2113572A1 (en) | 2005-03-11 | 2009-11-04 | Celera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
EP2471953A1 (en) | 2005-09-23 | 2012-07-04 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
EP2471952A1 (en) | 2005-09-23 | 2012-07-04 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
WO2007050705A2 (en) | 2005-10-26 | 2007-05-03 | Celera Diagnostics, Llc. | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof |
WO2008051511A2 (en) | 2006-10-20 | 2008-05-02 | Applera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
EP2431483A1 (en) | 2006-10-20 | 2012-03-21 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
EP2602332A1 (en) | 2007-11-05 | 2013-06-12 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
WO2009061799A2 (en) | 2007-11-05 | 2009-05-14 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
EP3048175A1 (en) | 2008-02-20 | 2016-07-27 | Celera Corporation | Genetic polymorphism associated with stroke, therapy based on the detection of the polymorphism and use of kits containing reagents for detecting the polymorphism |
EP3093351A1 (en) | 2008-07-09 | 2016-11-16 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
EP2733222A1 (en) | 2008-07-09 | 2014-05-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
EP2878680A1 (en) | 2008-07-09 | 2015-06-03 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
WO2011022633A2 (en) | 2009-08-21 | 2011-02-24 | Smithkline Beecham (Cork) Ltd. | Method of threating cancer |
EP3660508A1 (en) | 2010-04-19 | 2020-06-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases |
WO2011133418A1 (en) | 2010-04-19 | 2011-10-27 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
EP3056899A1 (en) | 2010-04-19 | 2016-08-17 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
US10878937B2 (en) | 2010-05-25 | 2020-12-29 | The Regents Of The University Of California | BamBam: parallel comparative analysis of high-throughput sequencing data |
US11133085B2 (en) | 2010-05-25 | 2021-09-28 | The Regents Of The University Of California | BAMBAM: parallel comparative analysis of high-throughput sequencing data |
US12040052B2 (en) | 2010-05-25 | 2024-07-16 | The Regents Of The University Of California | BamBam: parallel comparative analysis of high-throughput sequencing data |
US11164656B2 (en) | 2010-05-25 | 2021-11-02 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
WO2011147763A1 (en) | 2010-05-25 | 2011-12-01 | Glaxo Group Limited | Biomarkers |
US10706956B2 (en) | 2010-05-25 | 2020-07-07 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
US10726945B2 (en) | 2010-05-25 | 2020-07-28 | The Regents Of The University Of California | BAMBAM: parallel comparative analysis of high-throughput sequencing data |
US10825552B2 (en) | 2010-05-25 | 2020-11-03 | The Regents Of The University Of California | BAMBAM: parallel comparative analysis of high-throughput sequencing data |
US10825551B2 (en) | 2010-05-25 | 2020-11-03 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
US11158397B2 (en) | 2010-05-25 | 2021-10-26 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
US11152080B2 (en) | 2010-05-25 | 2021-10-19 | The Regents Of The University Of California | BAMBAM: parallel comparative analysis of high-throughput sequencing data |
US10971248B2 (en) | 2010-05-25 | 2021-04-06 | The Regents Of The University Of California | BamBam: parallel comparative analysis of high-throughput sequencing data |
US10991451B2 (en) | 2010-05-25 | 2021-04-27 | The Regents Of The University Of California | BamBam: parallel comparative analysis of high-throughput sequencing data |
WO2012061502A2 (en) | 2010-11-02 | 2012-05-10 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
EP3495500A1 (en) | 2010-11-02 | 2019-06-12 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
EP3045543A2 (en) | 2012-01-31 | 2016-07-20 | Novartis AG | Method of treating cancer |
WO2013113796A1 (en) | 2012-01-31 | 2013-08-08 | Smithkline Beecham (Cork) Limited | Method of treating cancer |
EP3795695A1 (en) | 2014-07-30 | 2021-03-24 | F. Hoffmann-La Roche AG | Genetic markers for predicting responsiveness to therapy |
Also Published As
Publication number | Publication date |
---|---|
EP0897567A2 (en) | 1999-02-24 |
WO1997040462A3 (en) | 1998-03-05 |
AU2734197A (en) | 1997-11-12 |
JP2000508912A (en) | 2000-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997040462A2 (en) | Correlating polymorphic forms with multiple phenotypes | |
Brown et al. | Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing | |
US6140047A (en) | Method and kit for predicting susceptibility to asthma | |
Reich et al. | Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels | |
Weyand et al. | Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis. | |
Zhu et al. | Polymorphisms of the IL-4, TNF-α, and Fc α RI β genes and the risk of allergic disorders in At-risk infants | |
Eberhardt et al. | Associations of HLA-DRB and-DQB genes with two and five year outcome in rheumatoid arthritis. | |
JP2010526555A (en) | Polynucleotides associated with age-related macular degeneration and methods for assessing patient risk | |
Zhang et al. | Association of two polymorphisms of tumor necrosis factor gene with acute severe pancreatitis | |
JP2010529464A (en) | Biomarker for predicting anti-TNF responsiveness or non-responsiveness | |
CN110029158A (en) | A kind of marfan's syndrome detection panel and its application | |
Permutt et al. | Searching for type 2 diabetes genes in the post-genome era | |
MXPA06003828A (en) | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease. | |
Ateş et al. | Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behcet’s disease | |
AU2016351311B9 (en) | SCAP gene mutant and the application thereof | |
Santos et al. | Association of human leukocyte A, B, and DR antigens in Colombian patients with diagnosis of spondyloarthritis | |
Pandey et al. | TNF-α, IL1-β, and immunoglobulin (GM and KM) gene polymorphisms in sarcoidosis | |
CN110042153A (en) | A kind of detection method and its primer sets of SMN1 gene mutation | |
CN112553358A (en) | Application of microbial flora in cerebral apoplexy | |
CN104232650B (en) | The new Disease-causing gene of idiopathic calcification of basal ganglion and its encoding proteins matter and application | |
Larsen et al. | Genetic Variants in the Protein S (PROS1) Gene and Protein S Deficiency in a Danish Population | |
CN111647670A (en) | Nephrotic syndrome-related enterobacteria Faecaliallea and application thereof | |
Shen et al. | Identification of HLA-DQA1 as a susceptibility gene for spinal tuberculosis by exome sequencing | |
Hua et al. | Relationship between the regulatory region polymorphism of human tissue kallikrein gene and essential hypertension | |
CN108977449A (en) | The pathogenic mutation of primary immunodeficiency disease and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP KR MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997921244 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997921244 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWR | Wipo information: refused in national office |
Ref document number: 1997921244 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997921244 Country of ref document: EP |